Pharmacological hyperprolactinemia attenuates hydrocortisone-induced expression of CD11b on human CD8+ cells in vivo

Neuroimmunomodulation. 2004;11(3):133-40. doi: 10.1159/000076762.

Abstract

Objective: To study the short-term influences of pharmacologic hyperprolactinemia on hydrocortisone (HC)-induced effects on selected immune parameters.

Methods: A single dose of HC (40 mg per os) was administered to eleven healthy female volunteers 1 h after domperidone (10 mg per os) or placebo administration. Immune cell subsets and expression of adhesion molecules was assessed by flow cytometry at baseline and 4 and 6 h after HC administration. Intracellular staining of interleukin-4 (IL-4) and interferon-gamma (IFN-gamma) production in CD4+ lymphocytes after phorbol myristate acetate and ionomycin stimulation was performed at the same time points.

Results: HC administration was followed by a significant increase in cortisol levels, numbers of leukocytes and granulocytes and the percentage of CD16+, CD19+, CD11a+, CD11a+CD8+, CD11b+ and CD11b+CD8+ cells. The number of lymphocytes and monocytes and the percentage of CD3+, CD4+, CD4+/CD8+ ratio, CD62L+, CD54+ and CD54+CD16+ cells decreased, while the percentage of CD8+ cells was unaffected. Domperidone administration resulted in a significant increase in prolactin (PRL) concentrations. During hyperprolactinemia, the HC-induced increase in CD11b+CD8+ cells was significantly (p < 0.05) attenuated at 4 h. HC-induced changes in other immune parameters remained unaffected. No significant changes in the intracellular production of IL-4 and IFN-gamma in CD4+ lymphocytes were observed after a single dose of HC alone or during hyperprolactinemia.

Conclusions: This study shows an attenuated HC-induced increase in CD11b+CD8+ cells in the peripheral blood of healthy females during hyperprolactinemia. Our in vivo observations suggest that short-term interactions occur between PRL and glucocorticoids, affecting selected immune functions. Further studies are needed for confirmation of these results.

Publication types

  • Clinical Trial
  • Controlled Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antigens, CD / drug effects
  • Antigens, CD / immunology
  • CD11 Antigens / drug effects*
  • CD11 Antigens / immunology
  • CD11 Antigens / metabolism
  • CD8-Positive T-Lymphocytes / drug effects*
  • CD8-Positive T-Lymphocytes / immunology
  • CD8-Positive T-Lymphocytes / metabolism
  • Cell Adhesion Molecules / drug effects
  • Cell Adhesion Molecules / metabolism
  • Domperidone / pharmacology
  • Dopamine Antagonists / pharmacology
  • Drug Interactions / immunology
  • Female
  • Granulocytes / drug effects
  • Granulocytes / immunology
  • Humans
  • Hydrocortisone / blood
  • Hydrocortisone / pharmacology*
  • Hyperprolactinemia / blood
  • Hyperprolactinemia / chemically induced
  • Hyperprolactinemia / immunology*
  • Hypothalamo-Hypophyseal System / drug effects
  • Hypothalamo-Hypophyseal System / immunology
  • Hypothalamo-Hypophyseal System / metabolism
  • Interferon-gamma / immunology
  • Interferon-gamma / metabolism
  • Interleukin-4 / immunology
  • Interleukin-4 / metabolism
  • Lymphocyte Subsets / drug effects
  • Lymphocyte Subsets / immunology
  • Monocytes / drug effects
  • Monocytes / immunology
  • Pituitary-Adrenal System / drug effects
  • Pituitary-Adrenal System / immunology
  • Pituitary-Adrenal System / metabolism
  • Prolactin / agonists
  • Prolactin / blood
  • Prolactin / metabolism
  • Up-Regulation / drug effects
  • Up-Regulation / immunology

Substances

  • Antigens, CD
  • CD11 Antigens
  • Cell Adhesion Molecules
  • Dopamine Antagonists
  • Interleukin-4
  • Domperidone
  • Interferon-gamma
  • Prolactin
  • Hydrocortisone